TrialDiabetologia2021

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA

Tamara K Young et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.